Contemporary Immunosuppression Management and 1‐Year Outcomes in Dual Organ Heart Transplantation
- 8 August 2024
- journal article
- research article
- Published by Wiley in Clinical Transplantation
- Vol. 38 (8) , e15420
Abstract
Background: There have been limited reports on immunosuppression strategies and outcomes in dual organ heart transplant populations, primarily from before the 2018 United Network for Organ Sharing (UNOS) heart allocation policy change. Recent data suggested that outcomes with heart–lung and heart–liver transplants remained comparable in the new allocation era, yet heart–kidney recipients have worse 1‐year survival.Methods: This single‐center retrospective study evaluated adult heart–kidney, heart–liver, and heart–lung transplant recipients from September 2019 to May 2023. Immunosuppression regimen, infectious complications, and graft outcomes were collected for 12 months.Results: A total of 36 patients (kidney n = 20, liver n = 9, and lung n = 7) were included in this study. Basiliximab was the most commonly employed induction strategy across the organ groups (12/20 in kidney, 4/9 in liver, and 7/7 in lung). All patients were on triple immunosuppression at 12 months posttransplant with prednisone wean achieved in one heart–liver recipient. Infection complications were frequently reported (95% kidney, 75% liver, 100% lung group). One patient went back to dialysis due to focal segmental glomerulosclerosis. One chronic lung allograft dysfunction was reported, but no other severe biopsy‐proven rejection or retransplant was reported. The 1‐year survival was 85% (17/20) in heart–kidney, 78% (7/9) in heart–liver, and 86% (6/7) in heart–lung recipients.Conclusion: This study summarized real‐world immunosuppression strategies and outcomes in dual organ heart transplant recipients.Keywords
This publication has 32 references indexed in Scilit:
- Incidence of acute rejection and patient survival in combined heart–liver transplantationLiver Transplantation, 2022
- Increased Use of Multiorgan Transplantation in Heart Transplantation: Only Time Will TellThe Annals of Thoracic Surgery, 2020
- Simultaneous Heart–Liver Transplantation for Congenital Heart Disease in the United States: Rapidly Increasing With Acceptable OutcomesHepatology, 2020
- Risks and Epidemiology of Infections After Lung or Heart–Lung Transplantation2016
- Validation of a current definition of early allograft dysfunction in liver transplant recipients and analysis of risk factorsLiver Transplantation, 2010
- Long-Term Outcome of Lung and Heart-Lung Transplantation for Idiopathic Pulmonary Arterial HypertensionThe Annals of Thoracic Surgery, 2008
- Heart–lung and lung transplantation in grown-up congenital heart disease: long-term single centre experience☆European Journal of Cardio-Thoracic Surgery, 2007
- Revision of the 1990 Working Formulation for the Standardization of Nomenclature in the Diagnosis of Heart RejectionThe Journal of Heart and Lung Transplantation, 2005
- Report of the ISHLT Working Group on Primary Lung Graft Dysfunction Part II: Definition. A Consensus Statement of the International Society for Heart and Lung TransplantationThe Journal of Heart and Lung Transplantation, 2005
- Banff schema for grading liver allograft rejection: Utility in clinical practiceLiver Transplantation and Surgery, 1999